Genmab raises share capital via employee warrant exercise
Genmab A/S will issue 164,828 new shares after employees exercised warrants, generating about DKK 369.7 million for the company.
SEC filing
10 stories
Genmab A/S will issue 164,828 new shares after employees exercised warrants, generating about DKK 369.7 million for the company.
SEC filing
Data presented at SITC 2026 found neoantigen-specific T cells detectable directly ex vivo and a strong statistical link between AI-Immunology predictions and actual T-cell responses.
SEC filing, Drugs@FDA (9)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)
The October 20, 2026 deal gives Imunon equity, milestone payments up to $16.5 million, and royalties, while it keeps focus on its Phase 3 OVATION 3 trial.
SEC filing (5)
Genmab shareholders approved 2026 board remuneration on October 7, 2026, resulting in 5,300 restricted stock units granted to board members.
SEC filing
The phase II study combining DA-EPOCH chemotherapy with Jazz Pharmaceuticals' recombinant Erwinia asparaginase in newly diagnosed adult leukemia patients stays halted, per a registry update posted September 29, 2026.
SEC filing, ClinicalTrials.gov (2)
The Copenhagen-based biotech disclosed the awards in a September 24, 2026 filing tied to its equity compensation programs.
SEC filing